Cargando…
Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer
BACKGROUND: Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic marker in triple negative BC, a plethora of methods to assess im...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933637/ https://www.ncbi.nlm.nih.gov/pubmed/31878981 http://dx.doi.org/10.1186/s13058-019-1239-4 |
_version_ | 1783483246854537216 |
---|---|
author | Nederlof, Iris De Bortoli, Davide Bareche, Yacine Nguyen, Bastien de Maaker, Michiel Hooijer, Gerrit K. J. Buisseret, Laurence Kok, Marleen Smid, Marcel Van den Eynden, Gert G. G. M. Brinkman, Arie B. Hudecek, Jan Koster, Jan Sotiriou, Christos Larsimont, Denis Martens, John W. M. van de Vijver, Marc J. Horlings, Hugo M. Salgado, Roberto Biganzoli, Elia Desmedt, Christine |
author_facet | Nederlof, Iris De Bortoli, Davide Bareche, Yacine Nguyen, Bastien de Maaker, Michiel Hooijer, Gerrit K. J. Buisseret, Laurence Kok, Marleen Smid, Marcel Van den Eynden, Gert G. G. M. Brinkman, Arie B. Hudecek, Jan Koster, Jan Sotiriou, Christos Larsimont, Denis Martens, John W. M. van de Vijver, Marc J. Horlings, Hugo M. Salgado, Roberto Biganzoli, Elia Desmedt, Christine |
author_sort | Nederlof, Iris |
collection | PubMed |
description | BACKGROUND: Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic marker in triple negative BC, a plethora of methods to assess immune infiltration exists, and it is unclear how these compare to each other and if they can be used interchangeably. METHODS: Two experienced pathologists scored sTIL, intra-tumoral TIL (itTIL), and 6 immune cell types (CD3(+), CD4(+), CD8(+), CD20(+), CD68(+), FOXP3(+)) in the International Cancer Genomics Consortium breast cancer cohort using hematoxylin and eosin-stained (n = 243) and immunohistochemistry-stained tissue microarrays (n = 254) and whole slides (n = 82). The same traits were evaluated using transcriptomic- and methylomic-based deconvolution methods or signatures. RESULTS: The concordance correlation coefficient (CCC) between pathologists for sTIL was very good (0.84) and for cell-specific immune infiltrates slightly lower (0.63–0.66). Comparison between tissue microarray and whole slide pathology scores revealed systematically higher values in whole slides (ratio 2.60–5.98). The Spearman correlations between microscopic sTIL and transcriptomic- or methylomic-based assessment of immune infiltrates were highly variable (r = 0.01–0.56). Similar observations were made for cell type-specific quantifications (r = 0.001–0.54). We observed a strong inter-method variability between the omics-derived estimations, which is further cell type dependent. Finally, we demonstrated that most methods more accurately identify highly infiltrated (sTIL ≥ 60%; area under the curve, AUC, 0.64–0.99) as compared to lowly infiltrated tumors (sTIL ≤ 10%; AUC 0.52–0.82). CONCLUSIONS: There is a lower inter-pathologist concordance for cell-specific quantification as compared to overall infiltration quantification. Microscopic assessments are underestimated when considering small cores (tissue microarray) instead of whole slides. Results further highlight considerable differences between the microscopic-, transcriptomic-, and methylomic-based methods in the assessment of overall and cell-specific immune infiltration in BC. We therefore call for extreme caution when assessing immune infiltrates using current methods and emphasize the need for standardized immune characterization beyond TIL. |
format | Online Article Text |
id | pubmed-6933637 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69336372019-12-30 Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer Nederlof, Iris De Bortoli, Davide Bareche, Yacine Nguyen, Bastien de Maaker, Michiel Hooijer, Gerrit K. J. Buisseret, Laurence Kok, Marleen Smid, Marcel Van den Eynden, Gert G. G. M. Brinkman, Arie B. Hudecek, Jan Koster, Jan Sotiriou, Christos Larsimont, Denis Martens, John W. M. van de Vijver, Marc J. Horlings, Hugo M. Salgado, Roberto Biganzoli, Elia Desmedt, Christine Breast Cancer Res Research Article BACKGROUND: Breast cancer (BC) immune infiltrates play a critical role in tumor progression and response to treatment. Besides stromal tumor infiltrating lymphocytes (sTILs) which have recently reached level 1B evidence as a prognostic marker in triple negative BC, a plethora of methods to assess immune infiltration exists, and it is unclear how these compare to each other and if they can be used interchangeably. METHODS: Two experienced pathologists scored sTIL, intra-tumoral TIL (itTIL), and 6 immune cell types (CD3(+), CD4(+), CD8(+), CD20(+), CD68(+), FOXP3(+)) in the International Cancer Genomics Consortium breast cancer cohort using hematoxylin and eosin-stained (n = 243) and immunohistochemistry-stained tissue microarrays (n = 254) and whole slides (n = 82). The same traits were evaluated using transcriptomic- and methylomic-based deconvolution methods or signatures. RESULTS: The concordance correlation coefficient (CCC) between pathologists for sTIL was very good (0.84) and for cell-specific immune infiltrates slightly lower (0.63–0.66). Comparison between tissue microarray and whole slide pathology scores revealed systematically higher values in whole slides (ratio 2.60–5.98). The Spearman correlations between microscopic sTIL and transcriptomic- or methylomic-based assessment of immune infiltrates were highly variable (r = 0.01–0.56). Similar observations were made for cell type-specific quantifications (r = 0.001–0.54). We observed a strong inter-method variability between the omics-derived estimations, which is further cell type dependent. Finally, we demonstrated that most methods more accurately identify highly infiltrated (sTIL ≥ 60%; area under the curve, AUC, 0.64–0.99) as compared to lowly infiltrated tumors (sTIL ≤ 10%; AUC 0.52–0.82). CONCLUSIONS: There is a lower inter-pathologist concordance for cell-specific quantification as compared to overall infiltration quantification. Microscopic assessments are underestimated when considering small cores (tissue microarray) instead of whole slides. Results further highlight considerable differences between the microscopic-, transcriptomic-, and methylomic-based methods in the assessment of overall and cell-specific immune infiltration in BC. We therefore call for extreme caution when assessing immune infiltrates using current methods and emphasize the need for standardized immune characterization beyond TIL. BioMed Central 2019-12-26 2019 /pmc/articles/PMC6933637/ /pubmed/31878981 http://dx.doi.org/10.1186/s13058-019-1239-4 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Nederlof, Iris De Bortoli, Davide Bareche, Yacine Nguyen, Bastien de Maaker, Michiel Hooijer, Gerrit K. J. Buisseret, Laurence Kok, Marleen Smid, Marcel Van den Eynden, Gert G. G. M. Brinkman, Arie B. Hudecek, Jan Koster, Jan Sotiriou, Christos Larsimont, Denis Martens, John W. M. van de Vijver, Marc J. Horlings, Hugo M. Salgado, Roberto Biganzoli, Elia Desmedt, Christine Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer |
title | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer |
title_full | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer |
title_fullStr | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer |
title_full_unstemmed | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer |
title_short | Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer |
title_sort | comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933637/ https://www.ncbi.nlm.nih.gov/pubmed/31878981 http://dx.doi.org/10.1186/s13058-019-1239-4 |
work_keys_str_mv | AT nederlofiris comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT debortolidavide comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT barecheyacine comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT nguyenbastien comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT demaakermichiel comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT hooijergerritkj comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT buisseretlaurence comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT kokmarleen comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT smidmarcel comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT vandeneyndengertggm comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT brinkmanarieb comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT hudecekjan comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT kosterjan comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT sotiriouchristos comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT larsimontdenis comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT martensjohnwm comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT vandevijvermarcj comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT horlingshugom comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT salgadoroberto comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT biganzolielia comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer AT desmedtchristine comprehensiveevaluationofmethodstoassessoverallandcellspecificimmuneinfiltratesinbreastcancer |